Citations

Showing 10 of 108119 citations.

Defining clinically significant tumor size in vestibular schwannoma to inform timing of microsurgery during wait-and-scan management: moving beyond minimum detectable growth
Macielak, Robert J. , Wallerius, Katherine P. , Lawlor, Skye K., Lohse, Christine M. , Marinelli, John P. , Neff, Brian A., Driscoll, Colin L. W., Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | October 15, 2021 | Volume: 136 | Issue: 5 | Pages: 1289-1297

10.3171/2021.4.jns21465 | PMID 34653971 Get It

OBJECTIVE Detection of vestibular schwannoma (VS) growth during observation leads to definitive treatment at most centers globally. Although ≥ 2 mm represents an established benchmark of tumor growth on serial MRI studies, 2 mm of linear tumor growth is unlikely to significantly alter microsurgical outcomes. The objective of the current work was to ascertain where the magnitude of change in clinical outcome is the greatest based on size. METHODS A single-institution retrospective review of a consecutive series of patients with sporadic VS who underwent microsurgical resection between January 2000 and May 2020 was performed. Preoperative tumor size cutpoints were defined in 1-mm increments and used to identify optimal size thresholds for three primary outcomes: 1) the ability to achieve gross-total resection (GTR); 2) maintenance of normal House-Brackmann (HB) grade I facial nerve function; and 3) preservation of serviceable hearing (American Academy of Otolaryngology–Head and Neck Surgery class A/B). Optimal size thresholds were obtained by maximizing c-indices from logistic regression models. RESULTS Of 603 patients meeting inclusion criteria, 502 (83%) had tumors with cerebellopontine angle (CPA) extension. CPA tumor size was significantly associated with achieving GTR, postoperative HB grade I facial nerve function, and maintenance of serviceable hearing (all p < 0.001). The optimal tumor size threshold to distinguish between GTR and less than GTR was 17 mm of CPA extension (c-index 0.73). In the immediate postoperative period, the size threshold between HB grade I and HB grade > I was 17 mm of CPA extension (c-index 0.65). At the most recent evaluation, the size threshold between HB grade I and HB grade > I was 23 mm (c-index 0.68) and between class A/B and C/D hearing was 18 mm (c-index 0.68). Tumors within 3 mm of the 17-mm CPA threshold displayed similarly strong c-indices. Among purely intracanalicular tumors, linear size was not found to portend worse outcomes for all measures. CONCLUSIONS The probability of incurring less optimal microsurgical outcomes begins to significantly increase at 14–20 mm of CPA extension. Although many factors ultimately influence decision-making, when considering timing of microsurgical resection, using a size threshold range as depicted in this study offers an evidence-based approach that moves beyond reflexively recommending treatment for all tumors after detecting ≥ 2 mm of tumor growth on serial MRI studies.
A case of VEXAS syndrome with subtle morphologic findings
Horton, Rachel K. , Zheng, Gang

Mayo Clinic

Blood | October 14, 2021 | Volume: 138 | Issue: 15 | Pages: 1378-1378

10.1182/blood.2021012596 | PMID 34647982 Get It

Prognostic role of 11C‐choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy
Jimbo, Masaya , Andrews, Jack R. , Ahmed, Mohamed E. , Dundar, Ayca , Karnes, R. Jeffrey , Bryce, Alan H. , Kwon, Eugene D., Lowe, Val J. , Bold, Michael S., Bryce, Alan H , Kendi, Ayse T, Ahmed, Mohamed , Kendi, A. Tuba

Mayo Clinic

The Prostate | October 14, 2021 | Volume: 82 | Issue: 1 | Pages: 41-48

10.1002/pros.24246 | PMID 34633087 Get It

AbstractBackgroundWe sought to assess the prognostic utility of 11C‐choline positron emission tomography/computed tomography (PET/CT) in patients with metastatic castrate resistant prostate cancer (mCRPC) undergoing primary docetaxel chemotherapy.MethodsWe performed a single institution retrospective analysis of 77 mCRPC patients who were treated with 6 cycles of docetaxel chemotherapy, and who also underwent 11C‐choline PET/CT scans at baseline (before chemotherapy), mid‐course (after 3 cycles), and posttherapy (after 6 cycles). We evaluated treatment response based on percent change in blood pool‐corrected maximum standardized uptake value (SUVmax) of the target lesion on PET/CT, as well as percent change in serum prostate specific antigen (PSA). Logistic regression analysis was used to identify factors associated with complete treatment response. Progression free survival (PFS) analysis was performed using log‐rank test and shown on Kaplan–Meier plot.ResultsPercent change in blood pool‐corrected SUVmax on mid‐course scan was a significant predictor of complete response (odds ratio [OR]: 0.98, 95% confidence interval [CI]: 0.96–0.99, p = .0003), whereas percent change in PSA was not (OR: 0.99, 95% CI: 0.99–1.01, p = .6025). 57 of 77 patients (74%) achieved ≥20% reduction in blood pool‐corrected SUVmax on mid‐course; these patients were 3.6 times more likely to achieve complete response after full 6 cycles of docetaxel chemotherapy, compared to patients with <20% reduction in blood pool‐corrected SUVmax (OR: 3.56, 95% CI: 1.04–16.52, p = .0420). Median PFS in the complete response group was 35.1 months (95% CI: 26.0–52.7 months), compared to 9.4 months (95% CI: 6.9–13.0 months) in the incomplete response group (p = .0005).ConclusionsOur study showed that mid‐course and posttherapy 11C‐choline PET/CT evaluation for mCRPC patients undergoing primary docetaxel chemotherapy can predict full course treatment response and PFS, respectively. 11C‐choline PET/CT imaging may provide valuable prognostic information to guide treatment choices for patients with mCRPC.
Transvenous embolization of a cerebrospinal fluid–venous fistula for the treatment of spontaneous intracranial hypotension
Borg, Nicholas , Oushy, Soliman , Brinjikji, Waleed , Savastano, Luis , Brinjikji, Waleed , Oushy, Soliman H

Mayo Clinic

Journal of NeuroInterventional Surgery | October 14, 2021 | Volume: 14 | Issue: 9 | Pages: 948-948

10.1136/neurintsurg-2021-018160 | PMID 34649936 Get It

Cerebrospinal fluid–venous fistula is an increasingly recognized cause of spontaneous intracranial hypotension.1 The site of the leak is between the dural sleeve around a spinal nerve root and the surrounding foraminal veins. In appropriately investigated patients, transvenous embolization of the draining foraminal and paraspinal veins has been shown to be an effective way of treating the disease, with low periprocedural morbidity, improvement in symptoms and radiological appearances.2 Video 1 shows the technique employed in a typical case using Onyx (Medtronic, Minnesota, USA) to embolize a CSF–venous fistula at the right T10 neural foramen. Video 1 Video showing the technique for trans-venous embolization of a right T10 CSF-venous fistula for the treatment of spontaneous intracranial hypotension. The first section covers patient selection and work up, before then focusing on the technical aspects of navigating through the azygos system to the target foramen and completely occluding the pathway for CSF outflow.
Phytochemical investigation of Pimpinella serbica
Vučković, Ivan , Stikovic, Sonja, Stešević, Danijela , Trifunović, Snežana , Vuckovic, Ivan , Jadranin, Milka

Mayo Clinic

Journal of the Serbian Chemical Society | October 14, 2021 | Volume: 86 | Issue: 12 | Pages: 1241-1247

10.2298/jsc210816081v Get It

The plant species Pimpinella serbica (Vis.) Drude, endemic to West Balkans, belongs to the genus Pimpinella L. (Apiaceae) according to newer botanical classification. Initially, the plant was described as Pancicia serbica Vis. and long considered as a monotypic genus. Previous phytochemical investigations of this plant were limited to the essential oil analysis by the GC?MS method. This is first study that includes LC-DAD?MS screening of the extracts of the roots and aerial parts, followed by isolation of secondary metabolites using chromatographic techniques. Five compounds belonging to phenylpropanoids and polyacetylenes, well known for their bioactivities, were isolated and structurally determined by combined spectroscopic methods (UV, NMR, MS). Dillapiole (1), nothoapiole (2) and oplopantriol A 18-acetate (4) were found in both extracts, while falcarindiol (3) was isolated from the roots and dendrotrifidol (5) from the aerial parts only. The phytochemical profile of P. serbica L. supports its position in the Pimpinella L. genus.
Hepatocyte cultures: From collagen gel sandwiches to microfluidic devices with integrated biosensors
Hoyos‐Vega, José M. de , Hong, Hye Jin , Stybayeva, Gulnaz , Revzin, Alexander , de Hoyos-Vega, Jose M , Stybayeya, Gulnaz

Mayo Clinic

APL Bioengineering | October 14, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1063/5.0058798 | PMID 34703968 Get It

Hepatocytes are parenchymal cells of the liver responsible for drug detoxification, urea and bile production, serum protein synthesis, and glucose homeostasis. Hepatocytes are widely used for drug toxicity studies in bioartificial liver devices and for cell-based liver therapies. Because hepatocytes are highly differentiated cells residing in a complex microenvironment in vivo, they tend to lose hepatic phenotype and function in vitro. This paper first reviews traditional culture approaches used to rescue hepatic function in vitro and then discusses the benefits of emerging microfluidic-based culture approaches. We conclude by reviewing integration of hepatocyte cultures with bioanalytical or sensing approaches.
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, Peter , Hartmann, Karin , Schwaab, Juliana , Carter, Melody C. , Elberink, Hanneke Oude , Butterfield, Joseph H. , Üstün, Celalettin , Bonadonna, Patrizia , Sotlar, Karl , Jawhar, Mohamad , Siebenhaar, Frank , Broesby‐Olsen, Sigurd , Yavuz, Selim , Zanotti, Roberta , Nedoszytko, Bogusław , Hoermann, Gregor , Radia, Deepti , Sperr, Wolfgang R. , Schwartz, Lawrence B. , Reiter, Andreas , Arock, Michel , Horny, Hans‐Peter, Metcalfe, Dean D. , Sperr, Wolfgang , Valent, Peter , Arock, Michel , Akin, Cem , Álvarez‐Twöse, Iván , Brockow, Knut , Hermine, Olivier , Niedoszytko, Marek , Lyons, Jonathan J. , George, Tracy I. , Greiner, Georg , Bonadonna, Patrizia , Nilsson, Gunnar P. , Lange, Magdalena , Castells, Mariana , Muñoz‐González, Javier I. , Triggiani, Massimo , Kluin‐Nelemans, Hanneke C. , Galli, Stephen Joseph , Órfão, Alberto , Gotlib, Jason

Mayo Clinic

HemaSphere | October 14, 2021 | Volume: 5 | Issue: 11 | Pages: e646

10.1097/hs9.0000000000000646 | PMID 34901755 Get It

Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract. The World Health Organization classification divides the disease into prognostically distinct variants of cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Although this classification remains valid, recent developments in the field and the advent of new diagnostic and prognostic parameters created a need to update and refine definitions and diagnostic criteria in MC neoplasms. In addition, MC activation syndromes (MCAS) and genetic features predisposing to SM and MCAS have been identified. To discuss these developments and refinements in the classification, we organized a Working Conference comprised of experts from Europe and the United States in August 2020. This article reports on outcomes from this conference. Of particular note, we propose adjustments in the classification of CM and SM, refinements in diagnostic criteria of SM variants, including smoldering SM and BM mastocytosis (BMM), and updated criteria for MCAS and other conditions involving MC. CD30 expression in MC now qualifies as a minor SM criterion, and BMM is now defined by SM criteria, absence of skin lesions and absence of B- and C-findings. A basal serum tryptase level exceeding 20 ng/mL remains a minor SM criterion, with recognition that hereditary alpha-tryptasemia and various myeloid neoplasms may also cause elevations in tryptase. Our updated proposal will support diagnostic evaluations and prognostication in daily practice and the conduct of clinical trials in MC disorders.
Right radial nerve decompression for refractory radial tunnel syndrome
Kouloumberis, Pelagia , Noland, Shelley S. , Lee, Yeonsoo Sara , Kouloumberis, Pelagia E, Singh, Rohin

Mayo Clinic

Surgical Neurology International | October 14, 2021 | Volume: 12 | Issue: No issue available | Pages: 507

10.25259/sni_673_2021 | PMID 34754557 Get It

Background: Radial tunnel syndrome arises due to compression of the radial nerve through the radial tunnel.[1,5] The radial nerve divides into superficial and deep branches in the forearm. The deep branch travels posteriorly through the heads of the supinator where compression commonly occurs.[3,9,7] This syndrome results in pain in the hand and forearm with no motor weakness.[8] This condition can be treated conservatively with splinting and anti-inflammatory medication.[2,4,6] For cases of refractory radial tunnel syndrome, surgical management can be considered. Herein, we have presented a step-by-step video guide on how to perform a radial nerve decompression with a review of the relevant anatomy and surgical considerations. Case Description: A 68-year-old right-handed woman presented to the Mayo Clinic (Scottsdale, AZ) with the right elbow pain which radiated to the forearm causing significant difficulties with daily tasks. She had been dealing with worsening symptoms for 4 months. The patient’s history of gardening and clinical presentation allowed for diagnosis of radial tunnel syndrome. After conservative measures failed and other differential diagnoses were excluded, surgical decompression was recommended to treat her symptoms. The patient’s right arm was marked preoperatively between the brachioradialis and extensor carpi radialis longus (ECRL) muscles. The posterior cutaneous nerve of the forearm was identified which allowed for the determination of the interval between the brachioradialis and ECRL. Separation of the two muscles allowed for the identification of the radial sensory nerve. A nerve stimulator was used to confirm the sensory nature of this nerve. The nerve to the extensor carpi radialis brevis (ECRB) was identified and retracted with a vessel loop. Dorsal to the nerve to the ECRB is the posterior interosseous nerve (PIN), which was identified and retracted with a vessel loop. The fascia of the ECRB was divided both longitudinally and transversely and the supinator below was identified. The supinator muscle was carefully divided to further decompress the PIN. Informed consent for publication of this material was obtained from the patient. Conclusion: The patient tolerated the procedure well and reported significantly reduced pain at 7-month follow-up. To the best of our knowledge, video tutorials on this procedure have not been published. This video can serve as an educational guide for peripheral nerve specialists dealing with similar lesions.
Does MOSES pulse modulation reduce short-term catheter reinsertion following holmium laser enucleation of the prostate?
Klett, Dane , Baird, Bryce , Ball, Colleen T. , Dora, Chandler , Klett, Dane E , Dora, Chandler D , Baird, Bryce A

Mayo Clinic

Investigative and Clinical Urology | October 14, 2021 | Volume: 62 | Issue: 6 | Pages: 666

10.4111/icu.20210182 | PMID 34729966 Get It